Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 8/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1085466 | 0.86 | NR1H2 (0.48) | NR1H2SRCCHRM2CHRM1CHRM3 | |
| SCHEMBL29100351 | 0.86 | NR1H2 (0.48) | NR1H2SRCCHRM2CHRM1CHRM3 | |
| SCHEMBL8065917 | 0.86 | NR1H2 (0.48) | NR1H2SRCCHRM2CHRM1CHRM3 | |
| SCHEMBL3725714 | 0.86 | NR1H2 (0.48) | NR1H2SRCCHRM2CHRM1CHRM3 | |
| SCHEMBL8070913 | 0.86 | NR1H2 (0.48) | NR1H2SRCCHRM2CHRM1CHRM3 | |
| SCHEMBL2254798 | 0.86 | NR1H2 (0.48) | NR1H2SRCCHRM2CHRM1CHRM3 | |
| SCHEMBL2078108 | 0.85 | NR1H2 (0.35) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL2078104 | 0.85 | NR1H2 (0.35) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| SCHEMBL2078105 | 0.85 | NR1H2 (0.35) | NR1H2CHRM2CHRM1CHRM3HSD17B10 | |
| Hydrochloric Acid SCHEMBL25216485 | 0.85 | NR1H2 (0.47) | NR1H2SRCCHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11020398-B2 | Amino-pyrrolopyrimidinone compounds and methods of use thereof | ARQULE, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-11020398-B2 | Amino-pyrrolopyrimidinone compounds and methods of use thereof | ARQULE, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| EP-3504213-A1 | AMINO-PYRROLOPYRIMIDINONE COMPOUNDS AND METHODS OF USE THEREOF | ArQule, Inc. (US) | 2019-07-03 | — | — | EP | disclosed |
| US-20180055846-A1 | AMINO-PYRROLOPYRIMIDINONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. | 2018-03-01 | — | — | US | disclosed |
| US-20180055846-A1 | AMINO-PYRROLOPYRIMIDINONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. | 2018-03-01 | — | — | US | disclosed |
| US-20180055846-A1 | AMINO-PYRROLOPYRIMIDINONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. | 2018-03-01 | — | — | US | disclosed |
| WO-2018039310-A1 | AMINO-PYRROLOPYRIMIDINONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2018-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11020398-B2 | Amino-pyrrolopyrimidinone compounds and methods of use thereof | BTK, SYK, LCK | NR1H2 3490/4885SRC 10/4885CHRM2 3780/4885 |
| US-20180055846-A1 | AMINO-PYRROLOPYRIMIDINONE COMPOUNDS AND METHODS OF USE THEREOF | BTK, SYK, LCK | NR1H2 3490/4885SRC 10/4885CHRM2 3780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.